Johanna Bendell

Johanna Bendell has led early-phase clinical development programs for multiple agents now approved or in late-stage development for colorectal cancer, including investigation of novel adjuvant strategies in CRC. Her work at Sarah Cannon Research Institute facilitates access to first-in-human and phase I-II trials for patients with early and advanced CRC. She has contributed to the development of ctDNA-guided adjuvant approaches through investigational trials. Bendell is recognized for accelerating the clinical development pipeline for gastrointestinal cancers through network-based trial execution.